Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above

NCT04640402 is registered in ClinicalTrials.gov with Jiangsu Province Centers for Disease Control and Prevention as lead sponsor.

NCT NCT04640402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above
Lead sponsor
Jiangsu Province Centers for Disease Control and Prevention
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2020
Completion date
November 23, 2021
Enrollment
960 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19